Stella Gaenger
Overview
Explore the profile of Stella Gaenger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muendlein A, Heinzle C, Leiherer A, Brandtner E, Geiger K, Gaenger S, et al.
Clin Biochem
. 2023 Oct;
121-122:110675.
PMID: 37844682
Background: Heart failure confers a high burden of morbidity and mortality. However, risk prediction in heart failure patients still is limited. Blood-based biomarkers hold promise to improve clinical risk assessment....
2.
Geiger K, Muendlein A, Leiherer A, Gaenger S, Brandtner E, Wabitsch M, et al.
Mol Biol Rep
. 2023 Oct;
50(12):9833-9843.
PMID: 37843712
Background: Adipose tissue hypoxia plays a crucial role in the development of chronic low-grade systemic inflammation which has been associated with the pathogenesis of obesity-related diseases. Myricetin is a natural...
3.
Leiherer A, Muendlein A, Saely C, Geiger K, Brandtner E, Heinzle C, et al.
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834795
(1) Background: Ceramides are a new kind of lipid biomarker and have already been demonstrated to be valuable risk predictors in coronary patients. Patients with peripheral artery disease (PAD) are...
4.
Muendlein A, Heinzle C, Brandtner E, Leiherer A, Geiger K, Gaenger S, et al.
Breast Cancer Res Treat
. 2023 Jul;
201(3):571-576.
PMID: 37490173
Purpose: Apolipoprotein M (APOM) is a plasma apolipoprotein closely involved with lipid metabolism and inflammation. In vitro studies suggest that APOM may also have a tumor-suppressive role in breast cancer....
5.
Muendlein A, Geiger K, Heinzle C, Gaenger S, Winder T, Severgnini L, et al.
J Cancer Res Clin Oncol
. 2023 Feb;
149(9):6435-6444.
PMID: 36763171
Purpose: RAS mutations are predictors of an adverse outcome in EGFR-targeted therapies and have been proposed as prognostic biomarkers of survival in metastatic colorectal cancer (mCRC). The analysis of circulating...
6.
Muendlein A, Heinzle C, Leiherer A, Geiger K, Brandtner E, Gaenger S, et al.
Int J Cardiol
. 2022 Aug;
369:54-59.
PMID: 35944770
Background: Patients with peripheral artery disease (PAD) are at increased risk of cardiovascular events and mortality compared with non-PAD populations. Blood based biomarkers may improve clinical risk assessment. Recently, we...
7.
Muendlein A, Brandtner E, Leiherer A, Geiger K, Heinzle C, Gaenger S, et al.
Sci Rep
. 2022 Jun;
12(1):10168.
PMID: 35715556
Serum glypican-4 (GPC4) has been identified as an insulin-sensitizing adipokine serving as a marker for body mass index and insulin resistance in humans. The association of circulating GPC4 with kidney...
8.
Muendlein A, Brandtner E, Leiherer A, Geiger K, Heinzle C, Gaenger S, et al.
Data Brief
. 2022 May;
42:108142.
PMID: 35496482
This data article is associated to the research article titled 'Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients' (Muendlein et al., 2022). The...
9.
Decker T, Bichler M, Birtel A, Fischer G, Geiger K, Gaenger S, et al.
Oncol Res Treat
. 2022 Feb;
45(5):248-253.
PMID: 35220309
Introduction: Somatic evolution of the cancer genome resulting in genetically different subclones is thought to be involved in the development of treatment resistance but might also offer new therapeutic opportunities...
10.
Muendlein A, Brandtner E, Leiherer A, Geiger K, Heinzle C, Gaenger S, et al.
Atherosclerosis
. 2022 Feb;
345:33-38.
PMID: 35202959
Background And Aims: Glypican-4 (GPC4) is a cell surface protein, but can be released into circulation under various clinical conditions. The association of circulating GPC4 with the risk of future...